Can Type 2 Diabetics Take Vitamin C

Type 2 diabetes mellitus is one of the most common chronic illnesses in the world.¹ The major cause of death in individuals with this condition is macrovascular disease. Impaired endothelial function, characterized by reduced nitric oxide bioactivity, is an early feature of diabetes,² and endothelial dysfunction is now thought to have an important role in the pathophysiology of atherosclerosis.³ Deficiency of endothelium-derived nitric oxide affects vascular tone, leukocyte adhesion to the endothelium, platelet aggregation, and vascular smooth muscle proliferation. Endothelial dysfunction may also contribute to the increased arterial stiffness observed in type 2 diabetes.⁴ Increasing evidence suggests that arterial stiffness may be an important additional and independent risk factor for cardiovascular disease.⁵ Stiffening of the arterial tree increases the velocity and amplitude of pulse waves reflected from the periphery back to the heart.⁶ This results in larger reflected waves reaching the ascending aorta earlier and augmenting the central systolic pressure. Augmentation of central systolic pressure increases left ventricular workload and therefore myocardial oxygen demand.

Endothelial dysfunction in type 2 diabetes may be secondary to a number of factors such as hyperglycemia, insulin resistance, hypertension, or dyslipidemia. Ascorbic acid deficiency may also be important.^7,8 Plasma ascorbate concentrations are reduced in type 2 diabetes, and this does not appear to be due to inadequate dietary intake.⁹ In addition, the reductive enzymatic recycling of ascorbic acid may be attenuated.¹⁰ Ascorbate has a number of important biological functions, including enhancement of endothelial nitric oxide bioactivity.¹¹ Diminished tissue concentrations and impaired recycling of ascorbic acid may therefore exacerbate diabetic endothelial dysfunction.

Intra-arterial administration of ascorbic acid has been reported to reverse impaired endothelium-dependent vasodilation in a number of conditions associated with increased cardiovascular risk, including diabetes.^12,13 Ceriello et al¹⁴ have shown that a large bolus of intravenous ascorbate can reduce blood pressure in type 1 diabetes. Although the observed hypotensive effect was acute, it was short-lived. Pilot data of our own from patients with type 2 diabetes suggest that high-dose intravenous ascorbic acid can also acutely decrease systemic arterial stiffness, as assessed by the aortic augmentation index.¹⁵ We have therefore performed a randomized, double-blind, placebo-controlled study to investigate the hypothesis that chronic supplementation with oral ascorbic acid may help to reduce systemic arterial stiffness in type 2 diabetes.

Methods

Subjects

Patients with type 2 diabetes, 45 to 70 years of age and controlled with diet or oral hypoglycemic agents, were recruited from local outpatient clinics. The duration of illness was <10 years, and treatment was unchanged for 3 months before and during the study. Antihypertensive therapy was permitted, but diastolic blood pressure had to be <95 mm Hg. Other exclusion criteria included macrovascular disease, proliferative diabetic retinopathy, urinary albumin/creatinine ratio >3 mg/mmol, smoking, total cholesterol >8 mmol/L, triglycerides >5 mmol/L, and the use of antioxidants or hormone replacement therapy. The study had approval from the Research Ethics Committee of Queen's University Belfast, and all patients gave written informed consent.

Study Design

Study patients were randomly assigned in a double-blind manner to receive either oral ascorbic acid (500 mg daily) or matched placebo. The Pharmacy Department of the Royal Group of Hospitals, Belfast, was responsible for the supply and randomization of the medication. Patients were examined at baseline and after 4 weeks of the assigned treatment. Existing antihypertensive therapies were continued throughout the study period. The examinations were conducted in the morning after an overnight fast and involved the collection of blood and urine samples, the measurement of brachial arterial blood pressure, and the performance of pulse wave analysis. All medications were withheld on the morning of testing. Compliance was assessed by tablet count and measurement of plasma ascorbate concentration.

Blood Pressure Measurement and Pulse Wave Analysis

After 30 minutes of supine rest, brachial blood pressure was measured with the validated Omron HEM-705CP oscillometric sphygmomanometer.¹⁶ Measurements were made in triplicate and averaged. Central (ascending aortic) pressure waveforms were derived and analyzed using the technique of pulse wave analysis (SphygmoCor-Px; PWV Medical), as previously described.^17–22

The features of the central aortic pressure waveform are illustrated in Figure 1. Augmentation was defined as the difference between the second systolic peak (P₂; caused by wave reflection) and the first systolic peak (P₁; caused by left ventricular contraction). The augmentation index (AgIx) was this difference expressed as a percentage of the central pulse pressure. Because the AgIx is partly dependent on the heart rate,²¹ all the values reported in this study were corrected for a heart rate of 72 beats/min. The AgIx was used to estimate overall systemic arterial stiffness.²³ Pilot data from our unit allowed us to estimate reproducibility. In 54 diabetic and nondiabetic subjects, 21 to 66 years of age, the mean±SD of the difference between repeated measurements was 0.2±1.7%. This compares favorably with other published studies.^17,19

**Figure 1.** Central aortic pressure waveform. P₁ indicates first systolic peak; P₂, second systolic peak; IP, inflection point; Ag, augmentation (P₂-P₁); PP, pulse pressure; Tr, time to wave reflection; ED, ejection duration. Aortic augmentation index (AgIx)=Ag/PP.

The time to wave reflection (Tr) was the time between the foot of the pressure wave and the inflection point on the central pressure waveform and provided a measure of the transit time between the ascending aorta and the first main reflectance site (the aortic bifurcation). Tr was therefore used to assess aortic pulse wave velocity and hence aortic stiffness.²⁴

The subendocardial viability ratio (SEVR) was calculated as the ratio of the area under the central pressure time curve during diastole to that during systole. SEVR has been shown to be a measure of the propensity for myocardial ischemia on the basis of altered hemodynamic forces.²⁵

Biochemical and Hematologic Evaluation

At each visit, blood was sent to the hospital's biochemistry and hematology laboratories for measurement of plasma glucose, insulin, HbA_1c, and lipids. Plasma ascorbic acid concentrations were measured from samples of EDTA-anticoagulated blood, by means of the technique described by Vuillemier and Keck.²⁶

Statistical Analysis

Results were analyzed with the SPSS statistical package (SPSS Inc). Paired and unpaired 2-tailed Student t tests were used to compare characteristics within or between groups as appropriate. Two-way ANOVA for repeated measures was used to compare the effects of ascorbic acid with placebo. Data were reported as mean±SD unless otherwise stated.

Sample size calculations were based on pilot data from our unit, which showed that the standard deviation of the aortic augmentation index, in patients with type 2 diabetes, was 4.6%.¹⁵ Therefore, it was estimated that 15 patients per group would give 80% power, at the 5% level of significance, to detect an absolute difference in augmentation index of 5%.

Results

The baseline characteristics of the placebo and ascorbic acid treated groups are shown in Table 1. Fifteen patients were recruited to placebo and 15 to ascorbic acid. The groups were matched for age, gender, physical characteristics, glycemic control, dyslipidemia, and fasting plasma insulin levels. Physical and biochemical indexes did not change in either treatment group during the study period. In the placebo group, 6 patients had their diabetes treated with a sulfonylurea, 3 patients with a biguanide, and 3 patients a combination of the two. This was similar to the ascorbic acid group (8 patients, sulfonylurea; 4 patients, combination therapy). The number of patients taking antihypertensive medication was also comparable between the placebo (5 patients, ACE inhibitor; 2 patients, calcium antagonist) and ascorbic acid (7 patients, ACE inhibitor; 2 patients, calcium antagonist) groups. There were no changes in the dose or number of medications between the beginning and end of the study for either group. All patients returned for follow-up, and compliance was 100%, as evidenced from tablet count.

**TABLE 1. Baseline Characteristics of Placebo and Ascorbic Acid-Treated Groups**
Patient Characteristics	Placebo (n=15)	Ascorbic Acid (n=15)
Data are presented as mean±SD.
*Number (percentage) or †median (interquartile range), as appropriate.
Male/female	10/5	12/3
Age, y	57.9 (6.6)	61.0 (6.5)
Height, m	1.68 (0.07)	1.71 (0.12)
Weight, kg	80.6 (14.3)	83.5 (17.6)
Body mass index, kg/m²	28.6 (4.2)	28.6 (4.4)
Oral hypoglycemic therapy, n^*	12 (80)	12 (80)
Antihypertensive therapy, n^*	7 (46.7)	9 (60)
Glucose, mmol/L	9.4 (2.0)	9.3 (2.2)
Insulin, mU/L^†	8.7 (6.7)	9.3 (11.5)
HbA_1c, %	8.1 (0.8)	8.1 (1.3)
Total cholesterol, mmol/L	5.4 (0.7)	5.2 (0.8)
HDL cholesterol, mmol/L	1.3 (0.2)	1.1 (0.2)
LDL cholesterol, mmol/L	3.3 (0.6)	3.1 (0.7)
Triglycerides, mmol/L	1.9 (0.7)	2.2 (1.1)

Effect of Treatment on Hemodynamics

Brachial systolic, mean, and diastolic arterial blood pressures were similar in the two groups at baseline (Figure 2). However, after 1 month of treatment, ascorbic acid had a significant blood pressure-lowering effect. Brachial systolic pressure fell from 142.1±12.6 to 132.3±12.1 mm Hg (difference [95% CI] 9.9 [4.7, 15.0] mm Hg; P=0.001), mean pressure from 104.7±7.4 to 97.8±7.5 mm Hg (6.9 [3.9,9.9] mm Hg; P<0.001), brachial diastolic pressure from 83.9±4.8 to 79.5±6.0 mm Hg (4.4 [1.8, 7.0] mm Hg; P=0.003), and peripheral pulse pressure from 58.2±10.8 to 52.7±8.5 mm Hg (5.5 [0.9, 10.1] mm Hg; P=0.023). Placebo had no effect on blood pressure, and this difference between treatments was significant (P<0.01).

**Figure 2.** Effect of placebo and ascorbic acid treatments on brachial arterial blood pressure. Compared with placebo, ascorbic acid significantly decreased systolic (SBP), mean (MAP), and diastolic (DBP) arterial blood pressures (P<0.01, 2-way repeated-measures ANOVA). *P<0.01, **P<0.001 vs baseline value (paired Student t test).

Ascorbic acid also reduced the aortic augmentation index and increased the time taken for the reflected pulse pressure wave to reach the ascending aorta (Table 2). There was an improvement in the subendocardial viability ratio, but this response was not significantly different from placebo.

**TABLE 2. Effect of Placebo and Ascorbic Acid Treatment on the Central Aortic Hemodynamics Derived From Peripheral Pulse Wave Analysis**
	Placebo			Ascorbic Acid			ANOVA P
	Baseline	One Month	Difference (95% CI)	Baseline	One Month	Difference (95% CI)	ANOVA P
Hemodynamic data are presented as mean±SD. Final column shows the P value for 2-way repeated measures analysis of variance. HR indicates heart rate; ASP, aortic systolic pressure; ADP, aortic diastolic pressure; Ag, augmentation; AgIx, augmentation index (corrected for heart rate); Tr, time to wave reflection; and SEVR, subendocardial viability ratio.
*P<0.05,
†P<0.01,
‡P<0.001 vs baseline (paired t test).
HR, beats/min	75.1±10.1	73.4±8.0	1.7 (−0.6, 4.1)	74.9±9.3	72.1±8.6	2.8 (−0.3, 5.9)	0.565
ASP, mm Hg	129.7±11.7	128.7±11.8	1.0 (−3.5, 5.4)	130.1±12.4	120.0±12.3^‡	10.1 (5.7, 14.6)	<0.01
ADP, mm Hg	85.1±6.4	85.7±6.1	−0.6 (−2.8, 1.7)	84.9±4.8	80.5±6.2^†	4.3 (1.6, 7.1)	<0.01
Ag, mm Hg	11.9±4.7	11.7±4.3	0.2 (−1.8, 2.2)	11.9±5.4	9.1±3.8^*	2.8 (0.6, 5.0)	0.071
AgIx, %	28.0±7.4	27.5±6.7	0.5 (−1.6, 2.5)	26.8±5.5	22.5±6.8^†	4.3 (1.5, 7.1)	0.026
Tr, ms	138.5±10.2	138.1±8.9	0.4 (−2.1, 2.9)	137.1±12.6	143.4±9.2^†	−6.3 (−10.1, −2.5)	<0.01
SEVR, %	147.3±20.2	146.8±20.9	0.5 (−12.9, 13.9)	142.9±23.0	152.7±26.1^*	−9.8 (−18.6, −1.0)	0.180

Effect of Treatment on Plasma Ascorbic Acid

Plasma ascorbic acid concentrations were similar in both groups at baseline. After ascorbic acid supplementation, plasma levels increased from 43.3±19.3 to 78.1±19.5 μmol/L (P<0.001). As expected, no change was observed with placebo, and the difference between treatments was significant (P<0.01). There was an inverse correlation between mean arterial blood pressure and plasma ascorbic acid concentration (r=−0.39; P=0.002; Pearson correlation coefficient).

Discussion

Ascorbic acid (500 mg) by mouth daily for 4 weeks decreased blood pressure, reduced systemic arterial stiffness (as assessed by the augmentation index and pulse pressure), and increased aortic compliance (as assessed by the timing of the reflected pressure wave). The improvement in arterial stiffness after a relatively short treatment time suggests a functional rather than structural change in the vasculature. There is increasing evidence to suggest that nitric oxide plays an important role in the functional regulation of large-artery stiffness.²⁷ Enhanced endothelial nitric oxide bioactivity may explain our observed changes in blood pressure and arterial stiffness.

Ascorbic Acid and Endothelial Nitric Oxide Bioactivity

There are a number of mechanisms whereby ascorbic acid may increase nitric oxide bioactivity. Oxidative stress is increased in diabetes.²⁸ Free radicals such as the superoxide anion can degrade nitric oxide. Ascorbic acid is an extremely potent free radical scavenger and may thus protect nitric oxide from excessive degradation. However, it has recently been reported that supraphysiological concentrations of ascorbate are required to prevent the interaction of superoxide and nitric oxide.²⁹

LDL particles are small and dense in type 2 diabetes and are susceptible to oxidation.³⁰ Oxidized LDL is directly toxic to endothelial cells and can impair the endothelial production of nitric oxide. α-Tocopherol is a lipid-soluble antioxidant and protects LDL particles from oxidative attack. Ascorbate is required for the regeneration of α-tocopherol.¹¹ Ascorbic acid may thus prevent LDL oxidation, either through the recycling of α-tocopherol or by scavenging free radicals directly.

Ascorbic acid may also enhance endothelial nitric oxide synthase activity. This may be secondary to the regulation of redox state but may also be due to an increase in the intracellular content of tetrahydrobiopterin.³¹

Vascular smooth muscle is another potential site for the action of ascorbic acid. In vitro experiments have shown that guanylate cyclase sensitivity to nitric oxide may be enhanced after ascorbic acid administration.³²

Finally, ascorbic acid may reduce insulin resistance.^33,34 Insulin can cause endothelium-dependent, nitric oxide-mediated vasodilation.³⁵ By improving insulin sensitivity, ascorbic acid may increase nitric oxide release from the endothelium. It should be noted, however, that we observed no changes in glycemia or in fasting plasma insulin values.

Despite the possible mechanisms proposed above, to date only one small in vivo study in humans has provided direct evidence for oral ascorbic acid enhancement of nitric oxide bioactivity and corresponding reduction in arterial blood pressure.³⁶ A recent publication by Duffy et al³⁷ reaffirmed the findings of a previous report by the authors showing that chronic treatment of hypertensive patients with oral ascorbic acid, in a dose sufficient to double plasma levels, resulted in a reduction in mean arterial blood pressure of ≈10 mm Hg.³⁸ However, they were unable to show any beneficial effect of ascorbic acid on conduit vessel vasomotor function. Perhaps the plasma levels achieved with oral dosing have a greater effect on resistance vessels.

Ascorbic Acid and Cardiovascular Risk

A recent large, prospective population study confirmed previous epidemiologic evidence for an inverse relation between plasma ascorbic acid concentration and cardiovascular death.³⁹ This study showed that increasing plasma ascorbic acid concentration was strongly and independently associated with reduction in risk of death from all causes, cardiovascular disease, and ischemic heart disease, with a dose-response relation across the whole population distribution. We found in subjects with type 2 diabetes that a 34.8 μmol/L increase in plasma ascorbate reduced systolic blood pressure by 9.9 mm Hg. This is of similar magnitude to that reported by Duffy et al³⁸ in hypertensive patients. Interestingly, a controlled diet study has also shown an inverse relation between plasma ascorbate and blood pressure.⁴⁰ Further studies to elucidate the dose-response effect are warranted.

Unfortunately, results from randomized trials to test the influence of antioxidants on coronary event rates and prognosis have been disappointing. The HOPE and GISSI-Prevenzione trials failed to demonstrate any improvement in patients with coronary artery disease.^41,42 One explanation for the negative results may be the use of vitamin E (α-tocopherol) as the sole antioxidant supplement. When α-tocopherol reacts with a radical, it becomes the α-tocopheroxyl radical, which itself may participate in pro-oxidative events. As discussed earlier, adequate concentrations of ascorbate are required for the regeneration of α-tocopherol. Therapeutic use of vitamin E, without additional vitamin C, may therefore be scientifically unsound. A recent randomized controlled trial by Brown et al⁴³ has investigated the combined effects of vitamins E and C on cardiovascular risk reduction. This study examined the effect of simvastatin-niacin and antioxidant therapy (vitamin E, vitamin C, β-carotene, and selenium), alone and together, on secondary prevention. Significant beneficial clinical effects were, however, only observed in the simvastatin-niacin group, and it was concluded that there was little justification for the use of antioxidant vitamins for the prevention of cardiovascular events. This study did have a number of limitations. The study patients were not a uniform group and included diabetics (types 1 and 2) and nondiabetics, normotensives and hypertensives, and smokers and nonsmokers. The simvastatin-niacin group was smaller than the other groups and had a significantly lower prevalence of diabetes. Because diabetes is associated with a greater risk of cardiovascular complications, this difference between the groups may have affected the findings.

Not all randomized, controlled trials with ascorbic acid have shown a blood pressure-lowering effect.⁴⁴ Two negative studies by Lovat et al⁴⁵ and Ghosh et al⁴⁶ used doses of ascorbic acid similar to those used in our study. However, the patients in these studies were older than our patients, and they had much higher baseline blood pressures. The study by Lovat et al was also difficult to interpret because of possible interaction between the crossover periods. Ghosh et al did show a significant reduction in both systolic and diastolic blood pressures with ascorbic acid, but these became nonsignificant when the reductions were compared with the placebo responses. In addition, the placebo and ascorbic acid groups in this study were not evenly matched for baseline plasma ascorbate concentration.

Why, in our patient group, have we observed beneficial cardiovascular effects with ascorbic acid supplementation? There are a number of possibilities. Type 2 diabetic subjects have multiple risk factors for cardiovascular disease, for example, hyperglycemia, insulin resistance, dyslipidemia, and hypertension. Each of these factors, separately, may be associated with increased free radical generation.⁴⁷ Diabetic patients may therefore have greater levels of oxidative stress than other groups of patients at risk of cardiovascular disease and may respond more favorably to antioxidant supplementation. These patients may also be more deficient in ascorbate than the general population. Previous studies in type 2 diabetes have revealed diminished tissue levels and impaired recycling mechanisms for ascorbic acid.^9,10 The individuals in the study all came from Northern Ireland. This region has a high prevalence of cardiovascular disease.⁴⁸ It is therefore possible that genetic and/or environmental factors may also have influenced the response of our patients to treatment with ascorbic acid.

Study Limitations

It might be argued that we should only have studied normotensive type 2 diabetic patients and that the beneficial hemodynamic effects of ascorbic acid may only occur in diabetic subjects with raised blood pressure. However, hypertension is a common manifestation of type 2 diabetes and insulin resistance.⁴⁹ Inclusion of these subjects gives our study greater clinical relevance. Evidence that ascorbic acid had a beneficial effect in type 2 diabetes, independent of existing hypertension, comes from the fact that there was no correlation between baseline blood pressure and the fall in blood pressure after ascorbic acid supplementation. Also, blood pressure values in the diabetic patients were similar to those obtained in a group of healthy, older subjects studied by Fotherby et al.⁵⁰ This latter study reported no change in clinic blood pressure but a small decrease in daytime ambulatory systolic blood pressure (2.0±5.2 mm Hg) after 3 months of 500 mg per day ascorbic acid supplementation. Therefore, baseline blood pressure cannot explain the significant and clinically relevant blood pressure-lowering effects of ascorbic acid in type 2 diabetes. The reduction in systemic arterial stiffness and aortic stiffness could have been a consequence of the fall in blood pressure.⁶ However, previous experiments have shown that ascorbic acid can decrease arterial stiffness independent of blood pressure.^15,51

Perspectives

The incidence of type 2 diabetes is increasing worldwide, and patients with diabetes have a greatly increased risk of death from cardiovascular disease. This risk may be secondary to associated factors such as hyperglycemia, insulin resistance, dyslipidemia, and hypertension. Increased arterial stiffness has also been observed in type 2 diabetes. Stiffening of the arterial tree is now thought to be an important additional and independent risk factor for cardiovascular disease. Plasma ascorbate concentrations are known to be diminished in diabetes, and the recycling of ascorbic acid may be impaired. Experimental evidence suggests that acute parenteral administration of high-dose ascorbic acid may have beneficial vascular effects in diabetes. We have shown in this pilot study that chronic daily supplementation with 500 mg oral ascorbic acid can lower blood pressure and improve arterial stiffness in patients with type 2 diabetes. Strict control of blood pressure is known to reduce the incidence of macrovascular complications and death in these patients.⁵² Ascorbic acid supplementation may therefore be a useful and inexpensive adjunctive therapy. Priority funding should now be given to the performance of larger and longer studies.

The study was supported by a grant from the Research and Development Office for the Health and Personal Social Services in Northern Ireland.

Footnotes

Correspondence to Dr B.A. Mullan, Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland, BT12 6BA. E-mail [email protected]

References

1 Nathan DM. Treating type 2 diabetes with respect. Ann Intern Med . 1999; 130: 440–441.CrossrefMedlineGoogle Scholar
2 Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension . 1998; 31: 1047–1060.CrossrefMedlineGoogle Scholar
3 Ross R, Atherosclerosis: an inflammatory disease. N Engl J Med . 1999; 340: 115–126.CrossrefMedlineGoogle Scholar
4 Cockcroft JR, Webb DJ, Wilkinson IB. Arterial stiffness, hypertension and diabetes mellitus. J Hum Hypertens . 2000; 14: 377–380.CrossrefMedlineGoogle Scholar
5 Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor? Am J Epidemiol . 1994; 140: 669–682.CrossrefMedlineGoogle Scholar
6 Nichols WW, O'Rourke MF. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 4th ed. London, UK: Arnold; 1998. Google Scholar
7 May JM. How does ascorbic acid prevent endothelial dysfunction? Free Radic Biol Med . 2000; 28: 1421–1429.CrossrefMedlineGoogle Scholar
8 Price KD, Price CS, Reynolds RD. Hyperglycemia-induced ascorbic acid deficiency promotes endothelial dysfunction and the development of atherosclerosis. Atherosclerosis . 2001; 158: 1–12.CrossrefMedlineGoogle Scholar
9 Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH. Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet Med . 1994; 11: 893–898.CrossrefMedlineGoogle Scholar
10 Bode AM, Yavarow CR, Fry DA, Vargas T. Enzymatic basis for altered ascorbic acid and dehydroascorbic acid levels in diabetes. Biochem Biophys Res Commun . 1993; 191: 1347–1353.CrossrefMedlineGoogle Scholar
11 Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr . 1999; 69: 1086–1107.CrossrefMedlineGoogle Scholar
12 Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol . 1998; 31: 552–557.CrossrefMedlineGoogle Scholar
13 Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest . 1996; 97: 22–28.CrossrefMedlineGoogle Scholar
14 Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ. Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci . 1991; 81: 739–742.CrossrefMedlineGoogle Scholar
15 Mullan BA, Young IS, Harper R, McCance DR. Ascorbic acid can reduce insulin resistance and augmentation of central systolic pressure in patients with type 2 diabetes. Diabet Med . 2001; 18 (suppl 2): P168.Abstract.CrossrefGoogle Scholar
16 O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit . 1996; 1: 55–61.MedlineGoogle Scholar
17 Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens . 1998; 16: 2079–2084.CrossrefMedlineGoogle Scholar
18 Brooks B, Molyneaux L, Yue DK. Augmentation of central arterial pressure in type 1 diabetes. Diabetes Care . 1999; 22: 1722–1727.CrossrefMedlineGoogle Scholar
19 Filipovsky J, Svobodova V, Pecen L. Reproducibility of radial pulse wave analysis in healthy subjects. J Hypertens . 2000; 18: 1033–1040.CrossrefMedlineGoogle Scholar
20 Wilkinson IB, MacCallum H, Rooijmans DF, Murray GD, Cockcroft JR, McKnight JA, Webb DJ. Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM . 2000; 93: 441–448.CrossrefMedlineGoogle Scholar
21 Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol . 2000; 525: 263–270.CrossrefMedlineGoogle Scholar
22 Wilkinson IB, MacCallum H, Hupperetz PC, van Thoor CJ, Cockcroft JR, Webb DJ. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol . 2001; 530: 541–550.CrossrefMedlineGoogle Scholar
23 Wilkinson IB, Cockcroft JR, Webb DJ. Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol . 1998; 32 (suppl 3): S33–S37.MedlineGoogle Scholar
24 Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM. Wave reflections and cardiac hypertrophy in chronic uremia: influence of body size. Hypertension . 1993; 22: 876–883.LinkGoogle Scholar
25 Buckberg GD, Towers B, Paglia DE, Mulder DG, Maloney JV. Subendocardial ischemia after cardiopulmonary bypass. J Thorac Cardiovasc Surg . 1972; 64: 669–684.MedlineGoogle Scholar
26 Vuillemier JP, Keck E. Fluorometric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment. J Micronutrient Anal . 1989; 5: 25–34.Google Scholar
27 Cockcroft JR, Wilkinson IB, Webb DJ. The Trevor Howell Lecture: age, arterial stiffness and the endothelium. Age Ageing . 1997; 26: 53–60.CrossrefMedlineGoogle Scholar
28 West IC. Radicals and oxidative stress in diabetes. Diabet Med . 2000; 17: 171–180.CrossrefMedlineGoogle Scholar
29 Jackson TS, Xu A, Vita JA, Keaney JFJ. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res . 1998; 83: 916–922.CrossrefMedlineGoogle Scholar
30 Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation . 1997; 95: 1–4.CrossrefMedlineGoogle Scholar
31 Baker TA, Milstien S, Katusic ZS. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. J Cardiovasc Pharmacol . 2001; 37: 333–338.CrossrefMedlineGoogle Scholar
32 Murphy ME. Ascorbate and dehydroascorbate modulate nitric oxide-induced vasodilations of rat coronary arteries. J Cardiovasc Pharmacol . 1999; 34: 295–303.CrossrefMedlineGoogle Scholar
33 Paolisso G, Balbi V, Volpe C, Varricchio G, Gambardella A, Saccomanno F, Ammendola S, Varricchio M, D'Onofrio F. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics. J Am Coll Nutr . 1995; 14: 387–392.CrossrefMedlineGoogle Scholar
34 Hirashima O, Kawano H, Motoyama T, Hirai N, Ohgushi M, Kugiyama K, Ogawa H, Yasue H. Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. J Am Coll Cardiol . 2000; 35: 1860–1866.CrossrefMedlineGoogle Scholar
35 Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest . 1994; 94: 1172–1179.CrossrefMedlineGoogle Scholar
36 Rolla G, Brussino L, Carra R, Garbella E, Bucca C. Hypertension and ascorbic acid. Lancet . 2000; 355: 1271–1272.CrossrefGoogle Scholar
37 Duffy SJ, Gokce N, Holbrook M, Hunter LM, Biegelsen ES, Huang A, Keaney JF Jr, Vita JA. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol . 2001; 280: H528–H534.CrossrefMedlineGoogle Scholar
38 Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF Jr, Vita JA. Treatment of hypertension with ascorbic acid. Lancet . 1999; 354: 2048–2049.CrossrefMedlineGoogle Scholar
39 Khaw KT, Bingham S, Welch A, Luben R, Wareham N, Oakes S, Day N. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study: European Prospective Investigation into Cancer and Nutrition. Lancet . 2001; 357: 657–663.CrossrefMedlineGoogle Scholar
40 Block G, Mangels AR, Norkus EP, Patterson BH, Levander OA, Taylor PR. Ascorbic acid status and subsequent diastolic and systolic blood pressure. Hypertension . 2001; 37: 261–267.CrossrefMedlineGoogle Scholar
41 Valagussa F, Franzosi MG, Geraci E, Mininni N, Nicolosi GL, Santini M, Tavazzi L, Vecchio C, Marchioli R. Dietry supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Pervenzione trial. Lancet . 1999; 354: 447–455.CrossrefMedlineGoogle Scholar
42 Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med . 2000; 342: 154–160.CrossrefMedlineGoogle Scholar
43 Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med . 2001; 345: 1583–1592.CrossrefMedlineGoogle Scholar
44 Ness AR, Chee D, Elliott P. Vitamin C and blood pressure: an overview. J Hum Hypertens . 1997; 11: 343–350.CrossrefMedlineGoogle Scholar
45 Lovat LB, Lu Y, Palmer AJ, Edwards R, Fletcher AE, Bulpitt CJ. Double-blind trial of vitamin C in elderly hypertensives. J Hum Hypertens . 1993; 7: 403–405.MedlineGoogle Scholar
46 Ghosh SK, Ekpo EB, Shah IU, Girling AJ, Jenkins C, Sinclair AJ. A double-blind placebo-controlled parallel trial of vitamin C treatment in elderly patients with hypertension. Gerontology . 1994; 40: 268–272.CrossrefMedlineGoogle Scholar
47 Carr A, Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic Biol Med . 2000; 28: 1806–1814.CrossrefMedlineGoogle Scholar
48 Boreham C, Twisk J, Van Mechelen W, Savage M, Strain J, Cran G. Relationships between the development of biological risk factors for coronary heart disease and lifestyle parameters during adolescence: the Northern Ireland Young Hearts Project. Public Health . 1999; 113: 7–12.MedlineGoogle Scholar
49 Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension . 1995; 26: 869–879.CrossrefMedlineGoogle Scholar
50 Fotherby MD, Williams JC, Forster LA, Craner P, Ferns GA. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. J Hypertens . 2000; 18: 411–415.CrossrefMedlineGoogle Scholar
51 Wilkinson IB, Megson IL, MacCallum H, Sogo N, Cockcroft JR, Webb DJ. Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. J Cardiovasc Pharmacol . 1999; 34: 690–693.CrossrefMedlineGoogle Scholar
52 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ . 1998; 317: 703–713.CrossrefMedlineGoogle Scholar

Can Type 2 Diabetics Take Vitamin C

Source: https://www.ahajournals.org/doi/10.1161/01.HYP.0000039961.13718.00

Can Type 2 Diabetics Take Vitamin C